Stonehearth Capital Management LLC Acquires New Position in Eli Lilly and Company (NYSE:LLY)

Stonehearth Capital Management LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 265 shares of the company’s stock, valued at approximately $206,000.

Several other large investors also recently bought and sold shares of LLY. Modus Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $268,000. Burkett Financial Services LLC grew its stake in shares of Eli Lilly and Company by 4.1% in the 1st quarter. Burkett Financial Services LLC now owns 406 shares of the company’s stock valued at $316,000 after buying an additional 16 shares during the period. General Partner Inc. purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $467,000. Kapitalo Investimentos Ltda purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $305,000. Finally, HighPoint Advisor Group LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $9,878,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $891.46 on Wednesday. The firm has a market cap of $847.25 billion, a PE ratio of 131.29, a price-to-earnings-growth ratio of 1.93 and a beta of 0.36. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $894.87. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company’s 50 day moving average is $790.79 and its two-hundred day moving average is $723.56.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period last year, the business earned $1.62 EPS. The company’s revenue was up 26.0% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were issued a $1.30 dividend. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Argus increased their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday. Finally, BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $787.53.

View Our Latest Stock Analysis on Eli Lilly and Company

Insider Activity

In other news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 194,978 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98. Following the transaction, the insider now directly owns 97,583,810 shares of the company’s stock, valued at approximately $86,450,473,117.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 762,804 shares of company stock worth $648,109,138. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.